CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
LY2603618 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01341457
NCT01341457Phase 1Completed
CompareCT.gov

A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors

Eli Lilly and Company·interventional·Posted Apr 25, 2011·Updated Mar 1, 2019

In Brief

A Phase 1 clinical trial evaluating LY2603618 and Gemcitabine for Solid Tumors. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid advanced or metastatic tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2011
Enrollment StartMay 1, 2011
Primary CompletionJun 1, 2013
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.2 years ago

Interventions

LY2603618drug

Administered intravenously

Gemcitabinedrug

Administered intravenously